{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:06:25Z","timestamp":1792145185255,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.09.028","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:54:46Z","timestamp":1790265286000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Teclistamab for the treatment of autoantibody-mediated coagulation disorders"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9613-8658","authenticated-orcid":false,"given":"Johannes","family":"Thaler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Eischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Kammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kn\u00f6bl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.09.028_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2026.09.028_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2026.09.028_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2026.09.028_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.55563\/clinexprheumatol\/cc5taf","article-title":"Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience","volume":"39","author":"Agmon-Levin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jtha.2026.09.028_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2026.09.028_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jtha.2026.09.028_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11926-024-01148-7","article-title":"Antiphospholipid patients admitted in the intensive care unit: what must the rheumatologist know?","volume":"26","author":"Moyon","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2026.09.028_bib11","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.medcli.2024.02.011","article-title":"Catastrophic antiphospholipid syndrome: lessons from the \u201cCAPS Registry\u201d","volume":"163","author":"Rodriguez-Pinto","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jtha.2026.09.028_bib12","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network","volume":"12","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.09.028_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2026.09.028_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667515","article-title":"Case report: resetting the humoral immune response by targeting plasma cells with daratumumab in anti-phospholipid syndrome","volume":"12","author":"Pleguezuelo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2026.09.028_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.09.028_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"5 Suppl 14","key":"10.1016\/j.jtha.2026.09.028_bib19","first-page":"97","article-title":"Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy","volume":"26","author":"Treon","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtha.2026.09.028_bib20","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","article-title":"Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy","volume":"189","author":"Winter","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jtha.2026.09.028_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.13015","article-title":"On the road to eliminating long-lived plasma cells\u2014\"are we there yet?\"","volume":"303","author":"Markmann","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtha.2026.09.028_bib22","first-page":"1290","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"379","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.028_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103510","article-title":"Deciphering the clinical significance of longitudinal antiphospholipid antibody titers","volume":"23","author":"Chighizola","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2026.09.028_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.42459","article-title":"Fluctuation of anti-domain 1 and anti-beta(2)\u2014glycoprotein I antibody titers over time in patients with persistently positive antiphospholipid antibodies","volume":"75","author":"Chighizola","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626006185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626006185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:53:07Z","timestamp":1791863587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626006185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S1538783626006185"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.028","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teclistamab for the treatment of autoantibody-mediated coagulation disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}